- Advocates say GOP proposal would ration Medicaid for kids
A Republican proposal to reform Medicaid would ration care for one-third of U.S. kids, advocates said Friday.
First Focus, a bipartisan group, responded to the idea of per-capita Medicaid caps floated by Senate Finance Ranking Member Orrin Hatch (R-Utah) and Rep. Bill Cassidy (R-La.).
Hatch endorsed the policy last month as a way to reduce the deficit. Per-capita caps would limit Medicaid spending based on a beneficiary’s health condition and eligibility category — child, senior, disabled person, and so on.
- Roche Turkey Selects Vidyo to Significantly Reduce Travel, Costs and Enhance Productivity
HACKENSACK, NJ, January 30, 2013 – Vidyo, Inc., the first company to deliver personal telepresence, today announced that its award-winning video communications and collaboration solution was chosen by Roche Turkey, a subsidiary of the multinational healthcare company Roche Group. Vidyo’s solution was selected over a variety of other platforms, and was chosen primarily because it delivers superior quality video over standard IP networks, including the Internet, 4G and LTE and delivers seamless connectivity between room systems, desktops, laptops and mobile devices.
Prior to using Vidyo, Roche Turkey district managers had to routinely travel to headquarters in Istanbul. “Our employees often had to fly in the day before a meeting or stay overnight because of changeable flight schedules,” said Yavuz Şanes, IT Site Head Turkey, Roche Turkey. “Travel is not only tiring and stressful, but costly in terms of time and money. Our managers are greatly enthusiastic over Vidyo’s many different benefits. They have commented many times about how easy and efficient meetings have become through the use of Vidyo.”
To find the best video communications solution, Roche contracted Vitel, a highly regarded Systems Integrator in Turkey. “Vitel provided essential assistance during all phases of the project, from vendor selection to implementation,” said Şanes.
Throughout the entire Roche organization, and especially at Roche Turkey, innovation and sustainability are key goals. In September, 2012, Roche was recognized the most sustainable healthcare company in the world, topping the Dow Jones Sustainability Index (DJSI), for the fourth year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance. “Vidyo was a natural choice for Roche,” said Şanes. “The Vidyo platform is perfectly in line with the high value our organization places on environmental issues, because of Vidyo’s unique ability to enable our employees to meet and conduct business from wherever they are, whenever they want, without the negative environmental impact of travel.”
The fact that Vidyo allows Roche Turkey employees to access telepresence-quality video communications over an iPad using VidyoMobile™, has been one of the most noteworthy benefits to the company. In August of 2011, Roche distributed iPads to its field force of 200 people and since that time, they have needed only one single device for all of their communications needs. They are able to connect to conferences from wherever they are — over the Internet, 4G and even 3G, when corporate networks are not available. According to Roche Turkey’s calculations, in 2011, seven hundred employees participated in 216 video conferences eliminating the need for 447,000 kilometers of flight travel and 31,000 kilometers of road travel. Roche Turkey also asserts that by switching to Vidyo, transportation related risks for employees were reduced.
“Vidyo has again demonstrated the ease and value of its telepresence-quality video communications platform, delivering significant benefits,” said Eric LeGuiniec, VP and General Manager EMEA at Vidyo. “Roche Turkey is now able to conduct its business more effectively and increase the productivity of their employees by using Vidyo as the solution facilitates high-quality, natural visual communication on whatever device is convenient to Roche employees, regardless of location.”
The Vidyo Difference
The Vidyo communication and collaboration platform is software-based, highly flexible and can be easily customized for individual enterprise and vertical market video conferencing needs. The VidyoRouter™ is based on the company’s patented Adaptive Video Layering architecture and leverages the standard based Scalable Video Coding (SVC) technology. It eliminates the MCU and offers unprecedented error resiliency, low latency and rate matching enabling natural, affordable, high quality video to work over the Internet, LTE, 3G and 4G networks. The Vidyo platform allows users to quickly leverage the latest hardware innovations and new consumer devices, making it uniquely attractive to partners. Vidyo has been active driving H.264 SVC, HEVC and SIP videoconferencing interoperability in various standards bodies since 2005.
About Vidyo, Inc.
Vidyo, Inc. pioneered Personal Telepresence enabling natural, HD multi-point videoconferences on tablets and smart phones, PCs and Macs, room systems, gateways that interoperate with H.323 and SIP endpoints, telepresence solutions and affordable cloud-based visual communications solutions. Learn more at www.vidyo.com, on the Blog or follow@vidyo on Twitter.
- Sen. Menendez defends his relationship with political donor Melgen
Menendez said he didn’t do anything on his friend’s behalf that he doesn’t regularly do for others.
- PEPID Bridges Disease and Treatment Data, Responds to Industry Demands
Enhanced CDS allows EHR systems to identify harmful medications, offer safer alternatives
Phoenix, AZ — January 29, 2013 —PEPID has announced it is the first data provider to allow healthcare professionals to search for appropriate medications based on a patient’s diagnosis, and give alerts if it’s a hazardous treatment based on any of the patient’s conditions, procedures or diagnostics tests. This information can be integrated into any EMR or HIT system, and can help prevent potentially harmful treatment options, and provide safer alternatives.
With the increase in drugs and complex treatment plans, today’s healthcare professionals rely on clinical decision support tools for treatment information and to alert them if a hazardous combination exists. PEPID, recognized world-wide as a leading provider of developer drug data and clinical decision support resources, recently added drug-indication and drug-contraindication coding to its robust clinical decision support resources.
“As more demands are placed on healthcare professionals, and with more patients on multi-drug therapies, having access to robust medication information in one place is essential,” says John Wagner, PEPID president. “There was a need for this in the industry that was not being met – we wanted to better serve our customers by providing the clinical decision support needed to identify potentially harmful treatment options, modify treatment and easily identify alternatives without interrupting their workflow.”
This addition includes drug to disease checkers that alerts providers when a prescribed medication should not be used, due to an underlying disease, recent procedures or diagnostic test, or condition, such as pregnancy. This module also easily allows systems to link treatments to the conditions they treat, in order to identify safe, or cost-effective alternatives.
“We’re providing clinicians with the capability to allow systems to check against the patient history and alert the healthcare practitioner if a potentially hazardous combination exists,” says Edward Reynolds, PEPID chief technology officer. “We’ve also incorporated the latest healthcare terminology, including ICD-10.”
PEPID contains the most extensive drug database on the market today, along with thousands of disease profiles and medical conditions, medical and dosing calculators, drug interactions checker, illustrations, laboratory values and differential diagnosis generator. All PEPID’s clinical decision support data and tools can be integrated into any healthcare information system, EMR, EHR or EDIS to help meet requirements for meaningful use.
PEPID’s reputable clinical and pharmacological content is designed to support clinicians through every stage of the decision support process, increasing safety and accuracy through better-informed patient care, and this latest module adds to the robust content and tools available, and helps to meet meaningful use criteria in electronic medical records (EMR) systems.
Those attending HIMSS March 3-7, 2013 in New Orleans are encouraged to stop by PEPID’s booth #4837 to see a demonstration.
Learn more at pepid.com/indications-contraindications/
- Harris Corporation and Cancer Treatment Services International Team to Enhance Cancer Treatment and Availability
- A2iA Releases New Versions of its Data Extraction and Automatic Document Classification Software to Meet Market Demands
- EHR Association Responds to HIT Policy Committee Request for Comments on Stage 3 Meaningful Use
Digest powered by RSS Digest